Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.05.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Mary Sartor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Institute for Medical Research, Westmead, Sydney, New South Wales 2145, Australia. Hauptthemen laut MEDLINE: Plasma Cells, Multiple Myeloma, Paraproteinemias, Amyloidosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Industry, Innovation and Science, Australian Government.
Abstract (Originalsprache)
BACKGROUND: Kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) are antigens expressed on the surface of malignant plasma cells (PCs) that may have potential as immunotherapy targets. They arise from conformational epitopes in the constant regions of lipid-associated light chains and are not found on PCs in normal bone marrow (BM). MATERIALS AND METHODS: Antibodies to KMA and LMA (KappaMab, LambdaMab) and other antigens were used to compare the expression of KMA, LMA, B cell maturation antigen (BCMA), CD56 and SLAMF7 on bone marrow PCs. QuantiBrite beads were used to calculate antigen densities. LMA expression was evaluated in a panel of normal human and plasmacytoma tissues. RESULTS: Bone marrow aspirates (n = 195) were analyzed from patients with various clonal plasma cell dyscrasias (PCDs) (114 MM, 39 MGUS, 13 plasmacytoma, 9 SMM and 20 AL-amyloidosis). SLAMF7 expression was universal. KMA was present on 87 of 121 (72%) and LMA on 56 of 74 (76%) samples. BCMA expression exceeded KMA and LMA except in AL-amyloidosis, where KMA and LMA were expressed in 18 of 20 cases, including 4 in which LMA was expressed without BCMA. When all PCDs were considered, antigen density of KMA and LMA exceeded that of BCMA. LMA expression was restricted to malignant PCs and occasional mononuclear cells in normal mucosal associated lymphoid tissue. CONCLUSIONS: The broad and selective expression of KMA and LMA on malignant PCs and the high antigen density highlight the potential of these as valuable targets for immunotherapies in a variety of PCDs including AL-amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Westmead Institute for Medical Research, Westmead, Sydney, New South Wales 2145, Australia.
- TPL Path Labs GmbH, StageBio Company, Freiburg im Breisgau 79111, Germany.
- Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia; University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Parkvill…
- Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victor…
- Haemalogix Ltd, Sydney, New South Wales 2001, Australia.
- Westmead Institute for Medical Research, Westmead, Sydney, New South Wales 2145, Australia; Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, Sydney, New South Wales 21…
Förderung
- Department of Industry, Innovation and Science, Australian Government
Zitieren
APA
Sartor, M., Lemarchand, T. X., Britz, L., Er, J., Harrison, S. J., Dunn, R., & Gottlieb, D. J. (2025). Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.05.022
Vancouver
Sartor M, Lemarchand TX, Britz L, Er J, Harrison SJ, Dunn R, et al. Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.05.022
BibTeX
@article{Sartor2025,
author = {Sartor, Mary and Lemarchand, Thomas X and Britz, Luise and Er, Jeremy and Harrison, Simon J and Dunn, Rosanne and Gottlieb, David J},
title = {Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.05.022}
}
EUVIMED